We performed a systematic review and meta-analysis to quantify the efficacy and safety of FGF21 analogues in improving liver fibrosis in MASH.<h4>Methods</h4>We searched PubMed, Scopus, and the Cochrane Library (through February 2026) for randomized controlled trials (RCTs) comparing an FGF21 analogue versus placebo in adults with biopsy-confirmed MASH. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.